Saltar a búsqueda.
 Dow Descenso0.32% Nasdaq Descenso0.01%

Peregrine Pharmaceuticals, Inc. (PPHM)

-NasdaqCM
1.23 Descenso 0.02(1.60%) 31 de jul 4:00 PM GMT-4
|Después del cierre : 1.23 0.00 (0.00%) 31 de jul 5:37 PM GMT-4
Añadir a cartera
PerfilVer Perfil de:
Peregrine Pharmaceuticals, Inc.
14282 Franklin Avenue
Tustin, CA 92780
United States - Mapa
Teléfono: 714-508-6000
Fax: 714-838-5817
Sitio web: http://www.peregrineinc.com

Detalles 
Indices:N/C
Sector:Healthcare
Industria:Biotechnology
Empleados a tiempo completo:211

Resumen empresarial (en inglés) 

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment and diagnosis of cancer in the United States and internationally. The company’s lead immunotherapy candidate, bavituximab, which is in Phase III development stage for the treatment of previously-treated non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. It is also involved in the development of molecular imaging agent, 124I-PGN650, which is in exploratory clinical trial for the imaging of various solid tumor types. The company provides current good manufacturing practice services from cell line development to commercial biomanufacturing for its third-party customers. It has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

Estadísticas clave


Sitios web de la empresa 
Home Page
Búsqueda en Yahoo! de:
Más sobre Peregrine Pharmaceuticals, Inc.

Ejecutivos 
 PagarEjercido
Mr. Steven W. King , 51
Chief Exec. Officer, Pres, Director, Chief Exec. Officer of Avid Bioservices Inc and Pres of Avid Bioservices Inc
967.00mil0.00
Mr. Paul J. Lytle CPA, 47
Chief Financial Officer and Principal Accounting Officer
607.00mil0.00
Mr. Mark R. Ziebell J.D., 51
VP, Gen. Counsel and Corp. Sec.
540.00mil0.00
Dr. Shelley P. M. Fussey Ph.D., 49
VP of Intellectual Property
493.00mil0.00
Mr. Joseph S. Shan M.P.H., 42
VP of Clinical & Regulatory Affairs
445.00mil0.00
Las cantidades son con fecha de dic 31, 2014 y los valores de compensación son los del último año fiscal que finalizó en dicha fecha. Por sueldo se entiende salario, bonificaciones, etc. Ejercido representa el valor de las opciones ejercido durante el año fiscal.
Divisa en USD.
Ver ejecutivos